Table 2 Comparison between the two studied groups regarding MTX prescription data
Demographic variable | Group A (n = 60) | Group B (n = 30) | P value | |
|---|---|---|---|---|
MTX duration (month) | Mean ± SD | 38.3 ± 48.5 | 30.5 ± 32.0 | 0.467 |
Range | 4–168 | 1–120 | ||
MTX intolerance duration (month) | Mean ± SD | 19.5 ± 18.5 | 18.3 ± 17.7 | 0.798 |
Range | 3–60 | 1–60 | ||
Dose of MTX(mg) | Mean ± SD | 15.4 ± 4.3 | 14.7 ± 3.9 | 0.345 |
Range | 12.5–17.5 | 12.5–17.5 | ||
Route of administration n (%) | IM | 4 (6.7%) | 4 (13.3%) | 0.671 |
SC | 56 (93.3%) | 26 (86.7%) | ||
Medications to control intolerance n (%) | None | 12 (20%) | 6 (20%) | 0.532 |
Pantoprazole | 48 (80%) | 21 (70%) | ||
Antiemetics | 0 (0%) | 1 (3.3%) | ||
Pantoprazole + antiemetics | 0 (0%) | 2 (6.7%) | ||